Second line treatment of non-small cell lung cancer
10.3760/cma.j.issn.1673-422X.2015.05.018
- VernacularTitle:非小细胞肺癌二线治疗的进展
- Author:
Qini XU
;
Xuyuan LI
;
Hongbiao WANG
- Publication Type:Journal Article
- Keywords:
Lung neoplasms;
Drug therapy;
Anaplastic lymphoma kinase
- From:
Journal of International Oncology
2015;(5):385-387
- CountryChina
- Language:Chinese
-
Abstract:
The cytotoxic agents pemetrexed and docetaxel and the epidermal growth factor receptor (EGFR)tyrosine kinase inhibitors(TKIs)erlotinib and gefitinib are standard second-line therapies for non-small cell lung cancer. For patients without the EGFR mutation,more and more evidence has suggested the superiority of chemotherapy over targeted therapy. Adding targeted agents to standard second-line treatment is an trend of exploration,but without promising results nowadays. Crizotinib,targeting at anaplastic lymphoma kinase,has been shown excellent efficacy for second-line therapy in non-small cell lung cancer.
